CHRONIC MYELOMONOCYTIC LEUKEMIA-1
Clinical trials for CHRONIC MYELOMONOCYTIC LEUKEMIA-1 explained in plain language.
Never miss a new study
Get alerted when new CHRONIC MYELOMONOCYTIC LEUKEMIA-1 trials appear
Sign up with your email to follow new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA-1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo targets Hard-to-Treat leukemia
Disease control OngoingThis study tests two drugs together for people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. One drug is a targeted therapy that seeks out and kills cancer cells, while the other is a standard chemotherapy. The goal is to find the best dose and see if the comb…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA-1
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:13 UTC
-
New combo therapies aim to beat High-Risk blood cancers
Disease control OngoingThis study tests whether adding another drug (lenalidomide or vorinostat) to the standard chemotherapy azacitidine works better than azacitidine alone for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 282 adults took part…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA-1
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 12:11 UTC
-
New drug duo targets hard-to-treat blood cancers
Disease control OngoingThis study tests a new drug (seclidemstat) combined with a standard drug (azacitidine) for people with myelodysplastic syndromes or chronic myelomonocytic leukemia. The goal is to find the best dose and see if the combo can shrink or control the cancer. About 24 adults with these…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA-1
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:06 UTC